These defects in combination with other weaknesses already present in the insulin-signaling pathway in diabetic-proned patients might explain much of the reported increased risk of developing type 2 diabetes in rosuvastatin treated patients. The gene discussed is INS; the disease is type 2 diabetes mellitus.